Skip to main
ILMN

Illumina (ILMN) Stock Forecast & Price Target

Illumina (ILMN) Analyst Ratings

Based on 15 analyst ratings
Hold
Strong Buy 13%
Buy 33%
Hold 40%
Sell 7%
Strong Sell 7%

Bulls say

Illumina is considered the market leader in the next generation sequencing market and has a strong foothold in both the academic research and medical diagnostics market. The company's clinical segment, which makes up more than half of its revenue, has seen sustained growth in recent years, primarily driven by increased demand for oncology testing and screening applications. While competition in the market is strong, management has taken a proactive approach in addressing it by focusing on long-term strategies and building customer relationships rather than engaging in price wars. The company's focus on innovation, improved margins, and new product launches also bode well for its future growth potential. Overall, the sustainability of Illumina's business model, its strong financials, and progressive initiatives make it a favorable investment option in the life sciences tools industry.

Bears say

Illumina is facing several headwinds that could impact its financial performance in the near future. The company's reliance on the Chinese market has been hindered by their placement on the unreliable entity list, and there is no clear resolution in sight. Additionally, the recently announced partnership with SomaLogic is not expected to have a significant impact on revenue growth and could potentially dilute earnings. The company also faces competition from multiple players in the next-generation sequencing market, which could impact their market share and margins. As such, there are several risks to the company's outlook, including a decline in clinical growth, weak demand in the academic channel, and a continued decline in sales in China.

Illumina (ILMN) has been analyzed by 15 analysts, with a consensus rating of Hold. 13% of analysts recommend a Strong Buy, 33% recommend Buy, 40% suggest Holding, 7% advise Selling, and 7% predict a Strong Sell.

This aggregate rating is based on analysts' research of Illumina and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Illumina (ILMN) Forecast

Analysts have given Illumina (ILMN) a Hold based on their latest research and market trends.

According to 15 analysts, Illumina (ILMN) has a Hold consensus rating as of Jul 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $160.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $160.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Illumina (ILMN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.